Biomarker Summit 2012 Set for March 15-16 in San Diego, Ca, Announces Gtc

Printer-friendly versionPDF version

Pharmaceutical industry decision-makers, scientists, researchers, technology developers and investors will gather in one location at GTC’s Biomarker Summit 2012, March 15-16 in San Diego, CA.

PressReleasePoint-Creating a unique gathering place for the pharmaceutical industry, GTC is pleased to announce the Biomarker Summit 2012 to be held on March 15-16, 2012 at the Paradise Point Resort in San Diego.  The Summit will be the first of its kind to bring together biomarker development, diagnostics, oncology and business interests. 
 
Gaining cutting edge insight and perspective into the latest science, research and business applications and opportunities of biomarkers, delegates will not only learn but share their perspectives at this interactive event while taking advantage of networking opportunities.
 
Broken into four tracks, the Summit will include the 6^th Biomarker Development Conference, 4^th Oncology Biomarker Conference, Biomarkers & Diagnostics Conference and Biomarker Partnering & Deal-Making Conference. 
 
Offering delegates the choice to attend one track of the event or portions of all tracks allows attendees to hear from experts presenting their latest findings while maximizing the use of their time.  It is truly like attending four separate events at once.
 
The 6^th Biomarker Development Conference track will include discussion on issues including, next generation sequencing, personalized medicine, shortening development times, validation of preclinical to clinical studies, biomarkers in clinical trials, novel technologies and analytics.
 
The 4^th Oncology Biomarker Conference track will discuss challenges in clinical translation in oncology biomarkers, advancements in prognostic markers, early disease diagnosis, personalized oncology care, emerging technologies and development of targeted oncology biomarkers.
 
Biomarkers & Diagnostics Conference includes personalized medicine, next generation sequencing, patient selection in diagnostic clinical trials, novel approaches and technologies, companion diagnostics, circulating biomarkers, and statistical analysis of new biomarkers.
 
Finally, the Biomarker Partnering & Deal Making Conference track covers the business aspects of the biomarker industry by discussing biomarker investments in the current market, co-diagnostics partnering models, investor perspectives, strategic direction for partnering, novel technology developers, intellectual property rights concerning biomarkers and diagnostic reimbursements.
 
For additional details regarding the Biomarker Summit 2012, please visit www.gtcbio.com/BiomarkerSummit2012 or call (626) 256-6405.